Promising new therapy targets deadly childhood brain cancer in phase 3 trial
NCT ID NCT02887040
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study tests whether adding a drug combination called antineoplaston therapy (Atengenal and Astugenal) to standard radiation helps people aged 3-21 with a newly diagnosed, aggressive brainstem tumor (DIPG) live longer. About 92 participants will be randomly assigned to get either radiation alone or radiation plus the antineoplaston drugs. The main goal is to see if the combination improves overall survival and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN STEM GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.